Slimofit

Slimofit is a herbal medicine  for effective weight management and also help to lowering serum cholesterol. The main constituent in Slimofit  is chitosan. Chitosan is extracted from the shells of shrimp, lobster, and crabs. It is a fibrous substance that might block absorption of dietary fat and cholesterol.  Chitosan has been modified and optimized to enhance its solubility in stomach acid and fat binding performance.

Obesity :

Obesity is a serious health problem in the world. It is generally recognized that complications of the overweight state and obesity are responsible for thousands of deaths each year, because excess fat accumulation is associated with heart disease, stroke, and diabetes that significantly reduce life expectancy. Now Slimofit has become one possible solution to the problem.

In the digestive system, Slimofit complexes and binds with dietary fat in such a way that it is not absorbed by the body. Slimofit  is a unique and proprietary dietary fiber formulation, shown to significantly reduce body weight in a human clinical study.

Hypercholesterolemia :

Hypercholesterolemia is an important risk factor for cardiovascular disease. Orally administered chitosan binds lipids in the small intestine and reduces their absorption. Chitosan has been shown to decrease serum cholesterol in animal and human studies. This study investigated the effectiveness of chitosan in reducing serum cholesterol without concomitant diet therapy.

Clinical Study:

One recent study from Bangladesh found that rats given varying amounts of chitosan gained less weight and had lower cholesterol levels with increasing dosages. In addition, researchers found that chitosan reduced only the levels of the LDL (bad) cholesterol without affecting the levels of HDL (good) cholesterol. And chitosan appears to be useful for helping not only rats but humans lose fat.

Another recent study found that, Ninety female volunteers (age 34–70 y) with confirmed mild to moderate hypercholesterolemia were enrolled into the study. They were randomly assigned to receive chitosan  or placebo in a double-blind manner. Serum lipids, body weight and adverse events were assessed at baseline and after 28 and 56 days of treatment. Subjects maintained their usual diet and documented the type and gross amount of food consumed.

Results: Eighty-four subjects (41 chitosan, 43 placebo) were included in the analysis. Chitosan significantly  reduced total cholesterol compared to placebo. In a subgroup of subjects with over 60 y of age, chitosan group significantly reduced total and LDL cholesterol compared with placebo. Adverse effects were few; no serious events were reported.